GMM Pfaudler H1FY27 Results (NSE: GMMPFAUDLR)
Signal: Steady quarter
The read
The trajectory is demand-positive but margin-constrained: H1 revenue grew 17% to ₹1,989 crore and backlog reached a record ₹2,446 crore, while EBITDA fell 8% to ₹204 crore and margin was 10.2%. The transformation program and four-division structure are now the key catalysts for converting backlog into better profitability; debt repayment of approximately ₹116 crore improves financial flexibility.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹1,989 Cr | +17% | N/A |
| Net profit | ₹57 Cr | +20% | |
| EPS | ₹12.72 | N/A | |
| EBIT margin | 10.2% |
P&L walk
H1 revenue grew 17% to ₹1,989 crore and order backlog rose 14% to ₹2,446 crore, but EBITDA declined 8% to ₹204 crore and EBITDA margin was 10.2%, showing weak earnings conversion despite stronger demand; PAT rose 20% to ₹57 crore.
Key positives
- Order intake reached ₹2,204 crore in H1 FY27 and backlog rose 14% YoY to ₹2,446 crore, providing stronger stated revenue visibility for coming quarters.
- Revenue grew 17% YoY to ₹1,989 crore, with Q2 revenue up 18% YoY to ₹1,065 crore.
- Net debt was reduced by approximately ₹116 crore in H1 FY27, while CRISIL maintained the company’s AA- rating with a Stable Outlook.
- The group realigned leadership around four global divisions, and management stated that the transformation program is driving cost efficiencies and margin improvements, although the H1 EBITDA decline shows that the benefit is not yet visible in reported earnings.
Key concerns
- H1 EBITDA declined 8% to ₹204 crore despite 17% revenue growth, indicating weaker operating conversion of demand.
- The 10.2% H1 EBITDA margin is not accompanied by a disclosed year-ago margin in the release, limiting assessment of the claimed margin-improvement trajectory.
- PAT growth of 20% to ₹57 crore outpaced EBITDA growth despite EBITDA declining 8%; the filing does not disclose the bridge, so earnings quality cannot be fully assessed from the release.
Research and educational content only. Not investment advice.